Insulin Dose Calculation –
AI Learns Individual Insulin Demand of a Type 1 Diabetic in 1 Week

• Diafyt is First to Market for AI Insulin Calculation
• It is Medical Certified, Clinical Tested and Released to Market in Europe
• The Device Learns the User’s Individual Insulin Demand
• This Enables a Longer Life, Saves Money on Medication, Reduces Doctor’s Visits and Simplifies Living with Diabetes
• The Diafyt Smart Insulin Pen is - at Significantly Lower Cost - as Easy to Use as an Insulin Pump.

Project Description
The Insulin Dose Calculation project / diafyt MedTech is developing smart devices and AI software to automate diabetes therapy.

What do we need?
To enter the U.S. market, we are seeking access to funding and market players.

What do we offer?
Diafyt offers a novel technology to enter an unserved, fast-growing market of diabetes therapy automation, a device that can calculate the optimal amount of insulin at any time.

Meet this winning German Research-SME-Tandem on the virtual Matchmaking Tour, June 7-11, 2021!
Presented by InnoHealth USA 2021 – a campaign led by Fraunhofer-Gesellschaft as part of the initiative “Research in Germany” of the Federal Ministry of Education and Research.

Dr. René RICHTER + Dipl.-Ing. Thomas WUTTKE
Technische Universität Dresden + diafyt MedTech

• Thomas Wutke, CEO, Diabetic Engineering Degree in Robotics, Founder of diafyt MedTech
• Rene Richter, PhD in Electronics, (co)Inventor of 30+ Patents for Insulin Drug Delivery Devices, TU Dresden
• Tandem has known each other for 3 years and is working on R&D projects of smart insulin pens with a patent pending.

For tandem video and further information please scan QR-code!